Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Cymbalta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Cymbalta was produced by Lilly and Shionogi.

Daily Brief: another departure at Gilead, veteran researcher to head up Karuna

Daily Brief: another departure at Gilead, veteran researcher to head up Karuna

Steven Paul, a veteran researcher who played a key role in developing Lilly’s antipsychotic and depression blockbuster drugs such as Zyprexa and Cymbalta is to head up efforts to find

Lilly mulls divestment of its animal health operations

Lilly mulls divestment of its animal health operations Alimta (pemetrexed) and antidepressant Cymbalta (duloxetine) resulting from generic competition.

Daiichi drug hits mark in shingles pain, but misses in other indications

Daiichi drug hits mark in shingles pain, but misses in other indications At the moment, there are just three approved drugs for fibromyalgia - Lyrica, Eli Lilly's Cymbalta (duloxetine) and Allergan's Savella (milnacipran) - and while these have been shown to reduce pain

Lilly’s president and chief executive John Lechleiter to retire

Lilly’s president and chief executive John Lechleiter to retire raloxifene) and antidepressant Cymbalta (duloxetine) have also expired.

UK court backs Actavis in dispute over Lilly's Alimta

UK court backs Actavis in dispute over Lilly's Alimta Maintaining Alimta's revenue stream is a priority for Lilly as it weathers the loss of patent protection for other brands, including osteoporosis drug Evista (raloxifene) and antidepressant Cymbalta (duloxetine) and

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Pills
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...

Infographics